CTIS2023-504751-28-00进行中（未招募）1 期
Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-group, active-control, observer-masked, superiority, randomised controlled surgical trial. - TIGER
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Males or females aged at least 50 years, Study eye 2.SMH, comprising sub-neuroretinal haemorrhage with or without sub- RPE haemorrhage, that occurs secondary to treatment naïve, or previously treated exudative AMD, including choroidal neovascularisation (CNV), idiopathic polypoidal choroidal vasculopathy (IPCV) and retinal angiomatous proliferation (RAP)., SMH involving the foveal centre that measures at least 1 disc diameter in greatest linear dimension., Sub-neuroretinal haemorrhage at least 125 microns thick, measured at the foveal centre using spectral-domain optical coherence tomography (SD-OCT)., BCVA between counting fingers and an Early Treatment of Diabetic Retinopathy Study (ETDRS) letter score of 70, inclusive.
排除标准
- •Serious allergy to fluorescein or indocyanine green (ICG)., SMH due to eye disease other than exudative AMD., Current active proliferative diabetic retinopathy., Current intraocular inflammation., Current ocular or periocular infection other than blepharitis., Current or known former high myopia (>6 dioptres)., Aphakia., Other current or pre-existing ocular conditions that, in the opinion of the Investigator, will preclude any improvement in BCVA following resolution of SMH, such as severe central macular atrophy or fibrosis, dense amblyopia, macular hole involving the fovea, or very poor BCVA prior to presentation with SMH (counting fingers or worse)., Inadequate pupillary dilation or significant media opacities, which will prevent adequate clinical evaluation of the posterior segment or fundus imaging., Intraocular surgery within 12 weeks of enrolment except for uncomplicated cataract surgery, which is permitted within 8 weeks of enrolment., Hypersensitivity to alteplase (Actilyse), gentamicin, arginine, phosphoric acid, polysorbate 80 or aflibercept (Eylea)., Stroke, transient ischaemic attack or myocardial infarction within 6 months, unless both the investigator and prospective participant consider that the ocular risks of withholding intravitreal anti-VEGF therapy exceed the potential systemic risks of arteriothrombotic events that have been variably reported in association with intravitreal anti- VEGF therapy. Given the very low dose of TPA (50 micrograms versus 15 to 90 milligrams), its delivery inside the blood ocular barrier, and very short half-life, many of the systemic risks of TPA are thought unlikely to apply., Participation in another interventional study within 12 weeks of enrolment or planned to occur during this study., Women who are breast feeding, pregnant, or planning to become pregnant during the clinical trial. Any sexually active women of childbearing potential must agree continued abstinence from heterosexual intercourse or to use highly effective methods of birth control for the duration up to 12 weeks post IMP administration. Men must also agree to use a condom if their partner is of child bearing potential, even if they have had a successful vasectomy. Females of childbearing potential are females who have experienced menarche and are not surgically sterilised (e.g. hysterectomy or bilateral salpingectomy) or post-menopausal (defined as at least 1 year since last regular menstrual period). Highly effective methods of birth control are those with a failure rate of < 1% per year when employed consistently and correctly, eg. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation via oral, intravaginal, and transdermal routes; progestogen-only hormonal contraception associated with inhibition of ovulation via oral, injectable, implantable, intrauterine device (IUD), or intrauterine hormonereleasing system ( IUS); or vasectomised partner., International Normalised Ratio (INR) greater than 3.5, unless it is anticipated that the INR can be brought below this level prior to vitrectomy, balancing the systemic risks with those of intraocular haemorrhage, Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial., Any other condition which, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical
研究者
相似试验
进行中（未招募）
1 期
A study of surgery to clear bleeding due to age-related macular degeneration.EUCTR2020-004917-10-DEKing's College London210
进行中（未招募）
1 期
A clinical trial of a clot dissolving drug and gas, injected into the eye, to treat bleeding associated with wet age-related macular degeneratioSub-macular haemorrhage secondary to wet macular degenerationMedDRA version: 16.0Level: PTClassification code 10064930Term: Age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 16.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2012-004078-24-GBKing's College London
招募中
不适用
vitreous surgery with intravitreal tissue plasminogen activator(t-PA)globe ruptureJPRN-UMIN000015282Okayama University Hospital30
招募中
不适用
Platelet Activation in Retinal Vein OcclusioBranch Retinal Vein OcclusionEye - Diseases / disorders of the eyeBlood - Other blood disordersACTRN12616001246471Ankara Ulucanlar Eye Education and research hospital.60
已完成
不适用
Plasmin Enzyme-assisted Vitrectomy for Pediatric Patients with Vitreoretinal Diseases in Taiwaposterior vitreous detachmentthe efficacy of plasmin-assisted vitrectomythe safety of plasmin-assisted vitrectomypediatricplasminretinavitrectomyvitreoretinopathyvitreousTCTR20140610001Chang Gung Medical Research Project (CMRPG381661)11